Subtype
Thyroid Gland Neoplasm
CI-CAN-00001600Explore in graph →
Non-malignant189 active trials10 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001600Explore in graph →
Clinical trials
891 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05837260 | Investigating Utility of ctDNA and Tumour Evolution in Advanced Thyroid Cancer(NOMINATE) | recruiting | — | 120 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 |
| clinicaltrials |
| NCT06530316 | RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer | recruiting | — | 48 | Fudan UniversityOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04472026 | AIM1: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid | completed | N/A | 66 | University of FloridaOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06530771 | Multimodality US Based on Angio Planewave Ultrasensitive Imaging and Shear Wave Elastography to Evaluate the Malignancy Risk Value of Thyroid Nodules | unknown | — | 720 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT02393690 | Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 60 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06523582 | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients | recruiting | — | 750 | Universidad Nacional Autonoma de MexicoOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06520319 | Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma | unknown | Phase 1 | 20 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT02383927 | Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations | completed | Phase 2 | 63 | Kura Oncology, Inc.INDUSTRY | 10 | Jul 11, 2024 | clinicaltrials |
| NCT01856920 | QUILT-3.006 for Recurrent Medullary Thyroid Cancer | completed | Phase 2 | 35 | NantCell, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05328076 | Parathyroid Vascularization During Total Thyroidectomy Using Indocyanine Green Angiography(ANGIO_PARA) | terminated | — | 22 | IRCCS San RaffaeleOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06468696 | Improvements in Thyroid Tumor Surgery and the Prognosis, Diagnosis, Recurrence and Metastasis of Patients | unknown | N/A | 170 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT04782856 | Energy Metabolism in Thyroidectomized Patients | completed | Phase 2 | 13 | Virginia Commonwealth UniversityOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | terminated | Phase 1 / Phase 2 | 41 | Turning Point Therapeutics, Inc.INDUSTRY | 2 | Jun 13, 2024 | clinicaltrials |
| NCT06443866 | I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer | recruiting | — | 50 | Miami Cancer Research Center, Inc.OTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT06437873 | Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTC | completed | — | 2,957 | Dezhou Hospital Qilu Hospital of Shandong UniversityOTHER | 0 | May 31, 2024 | clinicaltrials |
| NCT03776123 | Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients | completed | — | 347 | IpsenINDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT06432244 | The Effect of the Number of Central Lymph Nodes on Changes in Parathyroid Function | completed | — | 2,000 | Shandong Provincial HospitalOTHER_GOV | 1 | May 29, 2024 | clinicaltrials |
| NCT06432257 | The Effect of the Application of Head Mounted Magnifying Glasses on Postoperative PTH Changes in Thyroid Surgery | completed | — | 2,000 | Shandong Provincial HospitalOTHER_GOV | 1 | May 29, 2024 | clinicaltrials |
| NCT06429514 | Study on the Mechanism of Ganoderma Lucidum Spore Powder in the Treatment of Depression | completed | N/A | 298 | Ling ZhiqiangOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT06423105 | Influencing Factors and Prediction Model of False-negative Central Lymph Nodes in Thyroid Cancer Patients | completed | — | 6,369 | Ningning RenOTHER_GOV | 0 | May 23, 2024 | clinicaltrials |
| NCT06399159 | Prediction of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma Based on Ultrasound and Cytological Images | completed | — | 1,500 | Nanchong Central HospitalOTHER_GOV | 1 | May 22, 2024 | clinicaltrials |
| NCT05412680 | Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA)(TOETVA) | unknown | N/A | 60 | Fábio de Aquino CapelliOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT00537095 | Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer | completed | Phase 2 | 164 | Genzyme, a Sanofi CompanyINDUSTRY | 7 | Apr 19, 2024 | clinicaltrials |
| NCT03565536 | Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer | completed | Phase 2 | 18 | Fujian Medical UniversityOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT03757637 | Compare the Effects of NLSCP and Interactive ICT Supported HAP on Differentiate Diagnosed Thyroid Cancer Patients | unknown | N/A | 380 | National Taiwan University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT05684029 | Near-Infrared Autofluorescence With PTH Test Strip as an SOP of Parathyroid in Thyroid Surgery(PTFINDER) | completed | — | 101 | Fujian Medical UniversityOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT03470259 | Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging(TARGET) | completed | Phase 1 | 19 | University Medical Center GroningenOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05747365 | Role of Endocrine Disruptors in Thyroid Cancer(THY-ED) | unknown | — | 222 | Istituto Auxologico ItalianoOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06367010 | Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients | completed | — | 8 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06363123 | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis | unknown | — | 2,700 | Beijing Friendship HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06362694 | Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy | unknown | Phase 2 | 10 | Saint Petersburg State University, RussiaOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06362772 | Clinical Efficacy of 125I Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer | completed | — | 36 | Jiangxi Provincial Cancer HospitalOTHER | 0 | Apr 12, 2024 | clinicaltrials |
| NCT05132478 | The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer | completed | N/A | 126 | University of Wisconsin, MadisonOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT05624463 | Effect of Modified Endotracheal Intubation Protocol Combined With Early Oral Intake on Postoperative Recovery Quality in Thyroid and Parathyroid Surgery | completed | N/A | 200 | Peking Union Medical College HospitalOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06333587 | Minimally Invasive Treatments of the Thyroid(MIPA-MITT) | recruiting | — | 270 | European Institute of OncologyOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT04731740 | Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04739566 | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer(ANAPLAST-NEO) | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06325787 | Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma | completed | N/A | 1,021 | Chinese PLA General HospitalOTHER | 0 | Mar 25, 2024 | clinicaltrials |
| NCT04574947 | Lidocaine And Neuromonitoring in Thyroid Surgery | completed | Phase 4 | 110 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT03488134 | Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3 | completed | — | 74 | National Taiwan University HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT04354324 | Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma | unknown | N/A | 254 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06161233 | Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy(CAPABLE-IT) | completed | N/A | 56 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT02592356 | Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer | completed | N/A | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06283368 | Red Blood Cell Distributions (RDW, RDW-CW) and Lymphocyte Monocyte Ratios (LMR) for the Malignant Thyroid Nodules | completed | — | 172 | Kahramanmaras Sutcu Imam UniversityOTHER | 0 | Mar 1, 2024 | clinicaltrials |
| NCT06286631 | Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale | recruiting | — | 800 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03012620 | Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types(AcSé) | completed | Phase 2 | 334 | UNICANCEROTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05225259 | Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06277180 | 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC | recruiting | N/A | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 26, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 9, 2024source: clinicaltrials